Inhibition of Crmp1 Phosphorylation at Ser522 Ameliorates Motor Function and Neuronal Pathology in Amyotrophic Lateral Sclerosis Model Mice
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder that affects upper and lower motor neurons; however, its pathomechanism has not been fully elucidated. Using a comprehensive phosphoproteomic approach, we have identified elevated phosphorylation of Col...
Saved in:
Published in | eNeuro Vol. 9; no. 3; p. ENEURO.0133-22.2022 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Society for Neuroscience
01.05.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder that affects upper and lower motor neurons; however, its pathomechanism has not been fully elucidated. Using a comprehensive phosphoproteomic approach, we have identified elevated phosphorylation of Collapsin response mediator protein 1 (Crmp1) at serine 522 in the lumbar spinal cord of ALS model mice overexpressing a human superoxide dismutase mutant (SOD1
). We investigated the effects of Crmp1 phosphorylation and depletion in
mice using Crmp1
(Ser522→Ala) knock-in (
) mice in which the S522 phosphorylation site was abolished and
knock-out (
) mice, respectively.
/
mice showed longer latency to fall in a rotarod test while
/
mice showed shorter latency compared with
mice. Survival was prolonged in
/
mice but not in
/
mice. In agreement with these phenotypic findings, residual motor neurons and innervated neuromuscular junctions (NMJs) were comparatively well-preserved in
/
mice without affecting microglial and astroglial pathology. Pathway analysis of proteome alterations showed that the sirtuin signaling pathway had opposite effects in
/
and
/
mice. Our study indicates that modifying CRMP1 phosphorylation is a potential therapeutic strategy for ALS. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: T.A., H.N., and F.T. designed research; T.A., H.N., Y.Ka., M.T., Y.Ki., H.Taka., R.Y., and F.N. performed research; T.A., H.N., Y.Ka., M.T., Y.Ki., H.Taka., R.Y., H.S., T.I., H.K., S.K., S.H., K.Tak., M.K., K.Tan., Y.G., F.N., H.Take., H.D., and F.T. contributed unpublished reagents/analytic tools; T.A., H.N., Y.Ka., Y.Ki., H.Taka., R.Y., F.N., H.D., and F.T. analyzed data; T.A., H.N., Y.Ki., H.Taka., R.Y., F.N., H.D., and F.T. wrote the paper. This work was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research 18K15457 (to H.N.), Aa170030 (AdAMS; to H.D.), and 18K07532 (to F.T.); the Ministry of Health, Labour and Welfare Health Labour Sciences Research Grants 202011073A and 202011029A (to F.T.); the GlaxoSmithKline Japan Research Grant 2017 #F-17 (to H.N.); the Wakaba Research Fund (Research Fund for Potential Young Researchers; H.N.) from Yokohama Foundation for Advanced Medical Science; and the Yokohama City University Grant for Strategic Research Promotion SK2804 (to F.T.). The authors declare no competing financial interests. |
ISSN: | 2373-2822 2373-2822 |
DOI: | 10.1523/ENEURO.0133-22.2022 |